Dutch/Belgian Euronext- and Nasdaq-listed argenx, a global immunology innovation company, is to acquire Nasdaq-listed Forte Biosciences, a clinical-stage biopharmaceutical company, for US$77 per share in cash, representing a total equity…
Netherlands: argenx to acquire Forte Biosciences for US$2.2bn
…
…






